

Raed Alroughani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/208617/publications.pdf>

Version: 2024-02-01

120
papers

3,784
citations

172457

29
h-index

149698

56
g-index

127
all docs

127
docs citations

127
times ranked

3548
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969.	3.0	6
2	Recombinant hepatitis B vaccine uptake and multiple sclerosis risk: A marginal structural modeling approach. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103487.	2.0	1
3	Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210771.	1.0	2
4	Multiple Sclerosis Relapses Following Cessation of Fingolimod. <i>Clinical Drug Investigation</i> , 2022, 42, 355-364.	2.2	8
5	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	3.0	2
6	Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East. <i>Journal of Clinical Neuroscience</i> , 2022, 99, 311-316.	1.5	3
7	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	3.3	3
8	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	12
9	Risk factors of white matter hyperintensities in migraine patients. <i>BMC Neurology</i> , 2022, 22, 159.	1.8	5
10	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	3.3	1
11	O36â€¦ Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A24.3-A25.	1.9	0
12	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
13	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	3.0	7
14	The MSBase pregnancy, neonatal outcomes, and womenâ€™s health registry. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110091.	3.5	6
15	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
16	Primary Headache Disorder Among School Students in Kuwait. <i>Frontiers in Neurology</i> , 2021, 12, 621017.	2.4	4
17	A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon Î²-1a. <i>Multiple Sclerosis International</i> , 2021, 2021, 1-7.	0.8	2
18	Neuralgic amyotrophy associated with COVID-19 infection: a case report and review of the literature. <i>Neurological Sciences</i> , 2021, 42, 2161-2165.	1.9	25

#	ARTICLE	IF	CITATIONS
19	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
20	Real-world retrospective study of effectiveness and safety of FINGolimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). <i>Clinical Neurology and Neurosurgery</i> , 2021, 203, 106576.	1.4	2
21	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alectuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2021, 10, 803-818.	3.2	2
22	Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19. <i>Neurology and Therapy</i> , 2021, , 1-17.	3.2	6
23	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. <i>CNS Drugs</i> , 2021, 35, 1097-1106.	5.9	7
24	004â€“...Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
25	Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study. <i>Journal of Headache and Pain</i> , 2021, 22, 97.	6.0	22
26	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8
27	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	4.7	21
28	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
29	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	9
30	MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103225.	2.0	16
31	Evaluation of disparities in multiple sclerosis risk by age, sex, and nativity in Kuwait:1980â€“2019. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102676.	2.0	0
32	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
33	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.1	168
34	Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101448.	2.0	7
35	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
36	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1765-1774.	3.0	10

#	ARTICLE	IF	CITATIONS
37	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.0	29
38	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1866-1876.	3.0	16
39	The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642095411.	3.5	3
40	Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106203.	1.4	6
41	Impact of Puberty in Girls on Prevalence of Primary Headache Disorder Among Female Schoolchildren in Kuwait. <i>Frontiers in Neurology</i> , 2020, 11, 594.	2.4	8
42	Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region. <i>Neurology and Therapy</i> , 2020, 9, 265-280.	3.2	18
43	Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106047.	1.4	2
44	Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. <i>Postgraduate Medicine</i> , 2020, 132, 368-376.	2.0	6
45	Family planning is the second most relevant factor for treatment decisions after disease activity â€œYes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 640-641.	3.0	2
46	A matched case-control study of risk factors associated with multiple sclerosis in Kuwait. <i>BMC Neurology</i> , 2020, 20, 64.	1.8	8
47	Replication analysis of variants associated with multiple sclerosis risk. <i>Scientific Reports</i> , 2020, 10, 7327.	3.3	7
48	Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine Patients. <i>Frontiers in Neurology</i> , 2020, 11, 633355.	2.4	1
49	Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521731985019.	1.0	1
50	Joinpoint Regression Analysis of Trends in Multiple Sclerosis Incidence in Kuwait: 1980â€“2019. <i>Neuroepidemiology</i> , 2020, 54, 472-481.	2.3	9
51	Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101409.	2.0	8
52	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	1.0	34
53	Economic burden of multiple sclerosis on Kuwait health care system. <i>PLoS ONE</i> , 2019, 14, e0216646.	2.5	4
54	Risk of relapses during pregnancy among multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 9-13.	2.0	25

#	ARTICLE	IF	CITATIONS
55	Expert opinion on clinical experience with subcutaneous interferon beta-1a in multiple sclerosis patients with different disease activity profiles. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 260-266.	0.4	0
56	An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. <i>Neurology and Therapy</i> , 2019, 8, 13-23.	3.2	22
57	Angiopoietin-like proteins in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 330, 31-34.	2.3	4
58	The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 19071.	3.3	13
59	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
60	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
61	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	7.4	336
62	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [<i>Mult. Scler. Relat. Disord.</i> (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	2.0	0
63	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	2.0	22
64	Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. <i>Neurology</i> , 2018, 90, e840-e846.	1.1	86
65	Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 56-62.	2.0	20
66	A longitudinal study of JC virus serostatus stability among multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 132-135.	2.0	3
67	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37
68	Use of traditional medicine for primary headache disorders in Kuwait. <i>Journal of Headache and Pain</i> , 2018, 19, 118.	6.0	29
69	Silent lesions on MRI imaging " Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	3.0	8
70	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.6	22
71	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	9.0	20
72	Pediatric multiple sclerosis: a review. <i>BMC Neurology</i> , 2018, 18, 27.	1.8	137

#	ARTICLE	IF	CITATIONS
73	Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A22.2-A22.	1.9	0
74	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
75	The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. <i>Pediatric Neurology</i> , 2017, 70, 56-60.	2.1	22
76	Assessment of plasma biomarkers for their association with Multiple Sclerosis progression. <i>Journal of Neuroimmunology</i> , 2017, 305, 5-8.	2.3	9
77	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
78	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
79	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	5.3	34
80	Sensitivity of visual evoked potentials and spectral domain optical coherence tomography in early relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 15-19.	2.0	14
81	Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?. <i>International Journal of Neuroscience</i> , 2017, 127, 944-951.	1.6	5
82	Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence. <i>Neurology and Therapy</i> , 2017, 6, 189-196.	3.2	19
83	Age-Period-Cohort Modeling of Multiple Sclerosis Incidence Rates in Kuwait: 1980-2014. <i>Neuroepidemiology</i> , 2017, 49, 152-159.	2.3	3
84	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	3.0	18
85	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
86	Burden of migraine in a Kuwaiti population: a door-to-door survey. <i>Journal of Headache and Pain</i> , 2017, 18, 105.	6.0	12
87	Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. <i>BMC Neurology</i> , 2017, 17, 150.	1.8	22
88	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-8.	0.8	30
89	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
90	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63

#	ARTICLE	IF	CITATIONS
91	Effects of prolonged fasting on fatigue and quality of life in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2016, 37, 929-933.	1.9	19
92	A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. <i>BMC Neurology</i> , 2016, 16, 240.	1.8	14
93	ZFAT gene variant association with multiple sclerosis in the Arabian Gulf population: A genetic basis for gender-associated susceptibility. <i>Molecular Medicine Reports</i> , 2016, 14, 3543-3550.	2.4	9
94	Risk Factors, Subtypes, and Outcome of Ischemic Stroke in Kuwait: A National Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 2145-2152.	1.6	16
95	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	1.9	76
96	A cortical stroke secondary to an isolated left ventricular noncompaction in a 29-year-old female. <i>Indian Heart Journal</i> , 2016, 68, S158-S160.	0.5	0
97	JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. <i>Journal of the Neurological Sciences</i> , 2016, 360, 61-65.	0.6	24
98	Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1086-1093.	3.0	14
99	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
100	Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?. <i>PLoS ONE</i> , 2016, 11, e0165846.	2.5	31
101	Yet another atypical presentation of anti-GQ1b antibody syndrome. <i>Neurology International</i> , 2015, 7, 5770.	2.8	0
102	Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait. <i>Journal of Neuroimmunology</i> , 2015, 285, 57-61.	2.3	13
103	Switch to natalizumab versus fingolimod in active relapsing/remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	5.3	143
104	Status migrainosus as an initial presentation of multiple sclerosis. <i>SpringerPlus</i> , 2015, 4, 28.	1.2	11
105	Functional clinical outcomes in multiple sclerosis: Current status and future prospects. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 192-201.	2.0	26
106	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	9.0	100
107	Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis. <i>Pediatric Neurology</i> , 2015, 53, 508-512.	2.1	12
108	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162

#	ARTICLE	IF	CITATIONS
109	Retinal nerve fiber layer thickness and neurologic disability in relapsingâ€“remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 359, 305-308.	0.6	23
110	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	3.0	36
111	Month of birth and risk of multiple sclerosis in Kuwait: A population-based registry study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 147-154.	3.0	16
112	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	2.5	122
113	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	3.0	73
114	Demographics and Clinical Characteristics of Multiple Sclerosis in Kuwait. <i>European Neurology</i> , 2014, 72, 181-185.	1.4	13
115	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.1	138
116	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	7.6	140
117	Migraine misdiagnosis as a sinusitis, a delay that can last for many years. <i>Journal of Headache and Pain</i> , 2013, 14, 97.	6.0	44
118	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	2.5	26
119	Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-6.	0.8	18
120	Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait. <i>International Journal of MS Care</i> , 2012, 14, 17-24.	1.0	2